Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

BACKGROUND. Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of early discontinuation due to intolerance was observed. We hypothesized that early changes in pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Kadakia, Kunal C., Snyder, Claire F., Kidwell, Kelley M., Seewald, Nicholas J., Flockhart, David A., Skaar, Todd C., Desta, Zereunesay, Rae, James M., Otte, Julie L., Carpenter, Janet S., Storniolo, Anna M., Hayes, Daniel F., Stearns, Vered, Henry, N. Lynn
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2016
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861358/
https://ncbi.nlm.nih.gov/pubmed/27009936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0349
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados